How India Exports Irbesartan to the World

In the United States, irbesartan is approved for the treatment of hypertension and diabetic nephropathy. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for irbesartan, indicating a competitive generic market. Notably, the FDA has not issued any import alerts specific to irbesartan, suggesting compliance with regulatory standards. The substantial export volume to the U.S. underscores the importance of maintaining stringent quality controls to meet FDA requirements.

In the European Union, irbesartan has been authorized for the treatment of essential hypertension and renal disease in hypertensive type 2 diabetic patients. For instance, the European Commission granted marketing authorization for Irbesartan BMS on January 19, 2007. However, this authorization was voluntarily withdrawn on November 11, 2009, due to commercial reasons, and the product was never marketed in the EU. Despite such withdrawals, other generic versions of irbesartan remain available in the European market. Manufacturers exporting to the EU and UK must adhere to Good Manufacturing Practice (GMP) standards as outlined by the European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA).

Irbesartan is included in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025, highlighting its significance in global health. This inclusion emphasizes the need for consistent quality and accessibility worldwide. Compliance with pharmacopoeial standards such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP) is essential to ensure product quality and facilitate international trade.

In India, irbesartan is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, irbesartan is not listed under the Drugs (Prices Control) Order (DPCO), allowing market-driven pricing. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) to comply with export regulations.

The primary patents for irbesartan have expired, leading to a robust generic market. This expiration has facilitated increased competition among manufacturers, contributing to the widespread availability and affordability of the drug globally.

In May 2025, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of irbesartan, which underscores its continued importance in treating hypertension and diabetic nephropathy. In January 2026, the FDA approved a new generic formulation of irbesartan, further enhancing market competition and accessibility. Additionally, in February 2026, the EMA issued updated guidelines on the manufacturing of angiotensin II receptor antagonists, including irbesartan, emphasizing the need for stringent impurity controls to ensure product safety.

These developments reflect the dynamic regulatory landscape surrounding irbesartan, highlighting the necessity for manufacturers and exporters to stay informed and compliant with evolving standards to maintain market access and ensure patient safety.

India is a prominent manufacturer of Active Pharmaceutical Ingredients (APIs), including Irbesartan. However, the production of these APIs often relies on Key Starting Materials (KSMs) sourced from China. According to the U.S. Pharmacopeia, 41% of KSMs used in U.S.-approved APIs are solely sourced from China, highlighting a significant dependency on Chinese suppliers.

This reliance poses a risk to the supply chain, as any disruption in China's production or export of KSMs can directly impact India's ability to manufacture APIs like Irbesartan. For instance, in November 2025, global supply chain issues, including shortages of ingredients and manufacturing supplies, led to intermittent and unpredictable disruptions in the availability of certain pharmaceutical products.

Our proprietary trade data indicates that the top five Indian exporters account for 76.1% of Irbesartan exports, with MACLEODS PHARMACEUTICALS LTD alone contributing 33.7% ($35.8M USD). This high concentration among a few suppliers increases the risk of supply disruptions if any of these key exporters face operational challenges.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic production of critical pharmaceutical ingredients and reduce import dependence. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules used in common antibiotics, marking a significant step towards self-reliance in API production.

Geopolitical tensions and shipping disruptions can significantly impact the pharmaceutical supply chain. For example, in July 2025, the FDA added pediatric ventricular assist devices to the medical device shortage list due to manufacturing problems and quality procedures at manufacturing facilities, compounded by global supply chain issues, including shortages of ingredients and components.

Additionally, the FDA has reported recalls of Angiotensin II Receptor Blockers (ARBs), including Irbesartan, due to the presence of nitrosamine impurities. These recalls, initiated in 2018 and continuing into 2026, have led to supply shortages and increased scrutiny of manufacturing processes.

• Diversify KSM Sourcing: Identify and qualify alternative suppliers for KSMs to reduce dependency on a single country, particularly China.

• Strengthen Supplier Relationships: Engage in strategic partnerships with multiple API manufacturers to distribute supply risk.

• Enhance Quality Control Measures: Implement rigorous quality assurance protocols to detect and prevent contamination issues, such as nitrosamine impurities.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events and assess their potential impact on the supply chain.

• Invest in Domestic Production: Support initiatives like the PLI scheme to bolster local manufacturing capabilities and reduce reliance on imports.

RISK_LEVEL: MEDIUM